메뉴 건너뛰기




Volumn 149, Issue , 2015, Pages 139-149

Co-targeting BRAF and cyclin dependent kinases 4/6 for BRAF mutant cancers

Author keywords

Abemaciclib; BRAF V600E; CDK4 6 inhibitor; Cyclin D1; Melanoma; Resistance

Indexed keywords

ANTINEOPLASTIC AGENT; B RAF KINASE; B RAF KINASE INHIBITOR; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 6; CYCLIN DEPENDENT KINASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE INHIBITOR;

EID: 84925641922     PISSN: 01637258     EISSN: 1879016X     Source Type: Journal    
DOI: 10.1016/j.pharmthera.2014.12.003     Document Type: Review
Times cited : (29)

References (141)
  • 1
    • 0028970609 scopus 로고
    • Transforming p21ras mutants and c-Ets-2 activate the cyclin D1 promoter through distinguishable regions
    • C. Albanese, J. Johnson, G. Watanabe, N. Eklund, D. Vu, and A. Arnold Transforming p21ras mutants and c-Ets-2 activate the cyclin D1 promoter through distinguishable regions J Biol Chem 270 1995 23589 23597
    • (1995) J Biol Chem , vol.270 , pp. 23589-23597
    • Albanese, C.1    Johnson, J.2    Watanabe, G.3    Eklund, N.4    Vu, D.5    Arnold, A.6
  • 2
    • 84865843828 scopus 로고    scopus 로고
    • The intermediate-activity (L597V)BRAF mutant acts as an epistatic modifier of oncogenic RAS by enhancing signaling through the RAF/MEK/ERK pathway
    • C. Andreadi, L.K. Cheung, S. Giblett, B. Patel, H. Jin, and K. Mercer The intermediate-activity (L597V)BRAF mutant acts as an epistatic modifier of oncogenic RAS by enhancing signaling through the RAF/MEK/ERK pathway Genes Dev 26 2012 1945 1958
    • (2012) Genes Dev , vol.26 , pp. 1945-1958
    • Andreadi, C.1    Cheung, L.K.2    Giblett, S.3    Patel, B.4    Jin, H.5    Mercer, K.6
  • 3
    • 84881431719 scopus 로고    scopus 로고
    • C-RAF mutations confer resistance to RAF inhibitors
    • R. Antony, C.M. Emery, A.M. Sawyer, and L.A. Garraway C-RAF mutations confer resistance to RAF inhibitors Cancer Res 73 2013 4840 4851
    • (2013) Cancer Res , vol.73 , pp. 4840-4851
    • Antony, R.1    Emery, C.M.2    Sawyer, A.M.3    Garraway, L.A.4
  • 6
    • 0035989912 scopus 로고    scopus 로고
    • Molecular regulation of melanocyte senescence
    • D.C. Bennett, and E.E. Medrano Molecular regulation of melanocyte senescence Pigment Cell Res 15 2002 242 250
    • (2002) Pigment Cell Res , vol.15 , pp. 242-250
    • Bennett, D.C.1    Medrano, E.E.2
  • 7
    • 19644397029 scopus 로고    scopus 로고
    • Adhesion control of cyclin D1 and p27Kip1 levels is deregulated in melanoma cells through BRAF-MEK-ERK signaling
    • K.V. Bhatt, L.S. Spofford, G. Aram, M. McMullen, K. Pumiglia, and A.E. Aplin Adhesion control of cyclin D1 and p27Kip1 levels is deregulated in melanoma cells through BRAF-MEK-ERK signaling Oncogene 24 2005 3459 3471
    • (2005) Oncogene , vol.24 , pp. 3459-3471
    • Bhatt, K.V.1    Spofford, L.S.2    Aram, G.3    McMullen, M.4    Pumiglia, K.5    Aplin, A.E.6
  • 9
    • 3542996265 scopus 로고    scopus 로고
    • Phase II trial of flavopiridol, a cyclin dependent kinase inhibitor, in untreated metastatic malignant melanoma
    • S. Burdette-Radoux, R.G. Tozer, R.C. Lohmann, I. Quirt, D.S. Ernst, and W. Walsh Phase II trial of flavopiridol, a cyclin dependent kinase inhibitor, in untreated metastatic malignant melanoma Invest New Drugs 22 2004 315 322
    • (2004) Invest New Drugs , vol.22 , pp. 315-322
    • Burdette-Radoux, S.1    Tozer, R.G.2    Lohmann, R.C.3    Quirt, I.4    Ernst, D.S.5    Walsh, W.6
  • 10
    • 54549108740 scopus 로고    scopus 로고
    • Comprehensive genomic characterization defines human glioblastoma genes and core pathways
    • Cancer Genome Atlas Research Network Comprehensive genomic characterization defines human glioblastoma genes and core pathways Nature 455 2008 1061 1068
    • (2008) Nature , vol.455 , pp. 1061-1068
  • 11
    • 84877028141 scopus 로고    scopus 로고
    • Comprehensive molecular portraits of human breast tumours
    • Cancer Genome Atlas Research Network Comprehensive molecular portraits of human breast tumours Nature 490 2012 61 70
    • (2012) Nature , vol.490 , pp. 61-70
  • 12
    • 84866894408 scopus 로고    scopus 로고
    • Comprehensive genomic characterization of squamous cell lung cancers
    • Cancer Genome Atlas Research Network Comprehensive genomic characterization of squamous cell lung cancers Nature 489 2012 519 525
    • (2012) Nature , vol.489 , pp. 519-525
  • 13
    • 84905029258 scopus 로고    scopus 로고
    • Comprehensive molecular profiling of lung adenocarcinoma
    • Cancer Genome Atlas Research Network Comprehensive molecular profiling of lung adenocarcinoma Nature 511 2014 543 550
    • (2014) Nature , vol.511 , pp. 543-550
  • 15
    • 0035282334 scopus 로고    scopus 로고
    • Mammalian MAP kinase signalling cascades
    • L. Chang, and M. Karin Mammalian MAP kinase signalling cascades Nature 410 2001 37 40
    • (2001) Nature , vol.410 , pp. 37-40
    • Chang, L.1    Karin, M.2
  • 18
    • 0031710479 scopus 로고    scopus 로고
    • The INK4a/ARF tumor suppressor: One gene-two products-two pathways
    • L. Chin, J. Pomerantz, and R.A. DePinho The INK4a/ARF tumor suppressor: One gene-two products-two pathways Trends Biochem Sci 23 1998 291 296
    • (1998) Trends Biochem Sci , vol.23 , pp. 291-296
    • Chin, L.1    Pomerantz, J.2    Depinho, R.A.3
  • 19
    • 22844445932 scopus 로고    scopus 로고
    • Use of human tissue to assess the oncogenic activity of melanoma-associated mutations
    • Y. Chudnovsky, A.E. Adams, P.B. Robbins, Q. Lin, and P.A. Khavari Use of human tissue to assess the oncogenic activity of melanoma-associated mutations Nat Genet 37 2005 745 749
    • (2005) Nat Genet , vol.37 , pp. 745-749
    • Chudnovsky, Y.1    Adams, A.E.2    Robbins, P.B.3    Lin, Q.4    Khavari, P.A.5
  • 20
    • 85047691154 scopus 로고    scopus 로고
    • Oncogenic AKAP9-BRAF fusion is a novel mechanism of MAPK pathway activation in thyroid cancer
    • R. Ciampi, J.A. Knauf, R. Kerler, M. Gandhi, Z. Zhu, and M.N. Nikiforova Oncogenic AKAP9-BRAF fusion is a novel mechanism of MAPK pathway activation in thyroid cancer J Clin Invest 115 2005 94 101
    • (2005) J Clin Invest , vol.115 , pp. 94-101
    • Ciampi, R.1    Knauf, J.A.2    Kerler, R.3    Gandhi, M.4    Zhu, Z.5    Nikiforova, M.N.6
  • 21
    • 84861863158 scopus 로고    scopus 로고
    • EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib
    • R.B. Corcoran, H. Ebi, A.B. Turke, E.M. Coffee, M. Nishino, and A.P. Cogdill EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib Cancer Discov 2 2012 227 235
    • (2012) Cancer Discov , vol.2 , pp. 227-235
    • Corcoran, R.B.1    Ebi, H.2    Turke, A.B.3    Coffee, E.M.4    Nishino, M.5    Cogdill, A.P.6
  • 24
    • 84873728334 scopus 로고    scopus 로고
    • Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance
    • M. Das Thakur, F. Salangsang, A.S. Landman, W.R. Sellers, N.K. Pryer, and M.P. Levesque Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance Nature 494 2013 251 255
    • (2013) Nature , vol.494 , pp. 251-255
    • Das Thakur, M.1    Salangsang, F.2    Landman, A.S.3    Sellers, W.R.4    Pryer, N.K.5    Levesque, M.P.6
  • 27
    • 84903843882 scopus 로고    scopus 로고
    • Molecular pathways: CDK4 inhibitors for cancer therapy
    • M.A. Dickson Molecular pathways: CDK4 inhibitors for cancer therapy Clin Cancer Res 20 2014 3379 3383
    • (2014) Clin Cancer Res , vol.20 , pp. 3379-3383
    • Dickson, M.A.1
  • 28
    • 84883062033 scopus 로고    scopus 로고
    • Continued response off treatment after BRAF inhibition in refractory hairy cell leukemia
    • S. Dietrich, J. Hullein, M. Hundemer, N. Lehners, A. Jethwa, and D. Capper Continued response off treatment after BRAF inhibition in refractory hairy cell leukemia J Clin Oncol 31 2013 e300 e303
    • (2013) J Clin Oncol , vol.31 , pp. e300-e303
    • Dietrich, S.1    Hullein, J.2    Hundemer, M.3    Lehners, N.4    Jethwa, A.5    Capper, D.6
  • 29
    • 0042743826 scopus 로고    scopus 로고
    • BRAF oncogenic mutations correlate with progression rather than initiation of human melanoma
    • J. Dong, R.G. Phelps, R. Qiao, S. Yao, O. Benard, and Z. Ronai BRAF oncogenic mutations correlate with progression rather than initiation of human melanoma Cancer Res 63 2003 3883 3885
    • (2003) Cancer Res , vol.63 , pp. 3883-3885
    • Dong, J.1    Phelps, R.G.2    Qiao, R.3    Yao, S.4    Benard, O.5    Ronai, Z.6
  • 30
    • 33748325763 scopus 로고    scopus 로고
    • Sorafenib in advanced melanoma: A Phase II randomised discontinuation trial analysis
    • T. Eisen, T. Ahmad, K.T. Flaherty, M. Gore, S. Kaye, and R. Marais Sorafenib in advanced melanoma: A Phase II randomised discontinuation trial analysis Br J Cancer 95 2006 581 586
    • (2006) Br J Cancer , vol.95 , pp. 581-586
    • Eisen, T.1    Ahmad, T.2    Flaherty, K.T.3    Gore, M.4    Kaye, S.5    Marais, R.6
  • 31
    • 84920841992 scopus 로고    scopus 로고
    • BRAF inhibitor dabrafenib in patients with metastatic BRAF-mutant thyroid cancer
    • [Epub ahead of print]
    • G.S. Falchook, M. Millward, D.S. Hong, A. Naing, S. Piha-Paul, and S.G. Waguespack BRAF inhibitor dabrafenib in patients with metastatic BRAF-mutant thyroid cancer Thyroid 2014 10.1089/thy.2014.0123 [Epub ahead of print]
    • (2014) Thyroid
    • Falchook, G.S.1    Millward, M.2    Hong, D.S.3    Naing, A.4    Piha-Paul, S.5    Waguespack, S.G.6
  • 33
    • 76049104235 scopus 로고    scopus 로고
    • PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro
    • R.S. Finn, J. Dering, D. Conklin, O. Kalous, D.J. Cohen, and A.J. Desai PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro Breast Cancer Res 11 2009 R77
    • (2009) Breast Cancer Res , vol.11 , pp. R77
    • Finn, R.S.1    Dering, J.2    Conklin, D.3    Kalous, O.4    Cohen, D.J.5    Desai, A.J.6
  • 34
    • 84855983664 scopus 로고    scopus 로고
    • Phase I, dose-escalation trial of the oral cyclin-dependent kinase 4/6 inhibitor PD 0332991, administered using a 21-day schedule in patients with advanced cancer
    • K.T. Flaherty, P.M. Lorusso, A. Demichele, V.G. Abramson, R. Courtney, and S.S. Randolph Phase I, dose-escalation trial of the oral cyclin-dependent kinase 4/6 inhibitor PD 0332991, administered using a 21-day schedule in patients with advanced cancer Clin Cancer Res 18 2012 568 576
    • (2012) Clin Cancer Res , vol.18 , pp. 568-576
    • Flaherty, K.T.1    Lorusso, P.M.2    Demichele, A.3    Abramson, V.G.4    Courtney, R.5    Randolph, S.S.6
  • 36
    • 84874225181 scopus 로고    scopus 로고
    • Effects of Raf dimerization and its inhibition on normal and disease-associated Raf signaling
    • A.K. Freeman, D.A. Ritt, and D.K. Morrison Effects of Raf dimerization and its inhibition on normal and disease-associated Raf signaling Mol Cell 49 2013 751 758
    • (2013) Mol Cell , vol.49 , pp. 751-758
    • Freeman, A.K.1    Ritt, D.A.2    Morrison, D.K.3
  • 37
    • 9444228344 scopus 로고    scopus 로고
    • Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts
    • D.W. Fry, P.J. Harvey, P.R. Keller, W.L. Elliott, M. Meade, and E. Trachet Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts Mol Cancer Ther 3 2004 1427 1438
    • (2004) Mol Cancer Ther , vol.3 , pp. 1427-1438
    • Fry, D.W.1    Harvey, P.J.2    Keller, P.R.3    Elliott, W.L.4    Meade, M.5    Trachet, E.6
  • 39
    • 84875740314 scopus 로고    scopus 로고
    • Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal
    • (pl1)
    • J. Gao, B.A. Aksoy, U. Dogrusoz, G. Dresdner, B. Gross, and S.O. Sumer Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal Sci Signal 6 2013 (pl1)
    • (2013) Sci Signal , vol.6
    • Gao, J.1    Aksoy, B.A.2    Dogrusoz, U.3    Dresdner, G.4    Gross, B.5    Sumer, S.O.6
  • 40
    • 5444227865 scopus 로고    scopus 로고
    • Guilty as charged: B-RAF is a human oncogene
    • M.J. Garnett, and R. Marais Guilty as charged: B-RAF is a human oncogene Cancer Cell 6 2004 313 319
    • (2004) Cancer Cell , vol.6 , pp. 313-319
    • Garnett, M.J.1    Marais, R.2
  • 41
    • 77953500573 scopus 로고    scopus 로고
    • Somatic alterations in the melanoma genome: A high-resolution array-based comparative genomic hybridization study
    • A. Gast, D. Scherer, B. Chen, S. Bloethner, S. Melchert, and A. Sucker Somatic alterations in the melanoma genome: A high-resolution array-based comparative genomic hybridization study Genes Chromosomes Cancer 49 2010 733 745
    • (2010) Genes Chromosomes Cancer , vol.49 , pp. 733-745
    • Gast, A.1    Scherer, D.2    Chen, B.3    Bloethner, S.4    Melchert, S.5    Sucker, A.6
  • 42
    • 84930696140 scopus 로고    scopus 로고
    • Preclinical characterization of the CDK4/6 inhibitor LY2835219: In-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine
    • L.M. Gelbert, S. Cai, X. Lin, C. Sanchez-Martinez, M. Del Prado, and M.J. Lallena Preclinical characterization of the CDK4/6 inhibitor LY2835219: In-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine Invest New Drugs 32 2014 825 837
    • (2014) Invest New Drugs , vol.32 , pp. 825-837
    • Gelbert, L.M.1    Cai, S.2    Lin, X.3    Sanchez-Martinez, C.4    Del Prado, M.5    Lallena, M.J.6
  • 43
    • 84863922124 scopus 로고    scopus 로고
    • Comprehensive molecular characterization of human colon and rectal cancer
    • Cancer Genome Atlas Network
    • Cancer Genome Atlas Network Comprehensive molecular characterization of human colon and rectal cancer Nature 487 2012 330 337
    • (2012) Nature , vol.487 , pp. 330-337
  • 45
    • 67349212438 scopus 로고    scopus 로고
    • Melanocytic nevus-like hyperplasia and melanoma in transgenic BRAFV600E mice
    • V.K. Goel, N. Ibrahim, G. Jiang, M. Singhal, S. Fee, and T. Flotte Melanocytic nevus-like hyperplasia and melanoma in transgenic BRAFV600E mice Oncogene 28 2009 2289 2298
    • (2009) Oncogene , vol.28 , pp. 2289-2298
    • Goel, V.K.1    Ibrahim, N.2    Jiang, G.3    Singhal, M.4    Fee, S.5    Flotte, T.6
  • 46
    • 0029119740 scopus 로고
    • Cell cycle control in mammalian cells: Role of cyclins, cyclin dependent kinases (CDKs), growth suppressor genes and cyclin-dependent kinase inhibitors (CKIs)
    • X. Grana, and E.P. Reddy Cell cycle control in mammalian cells: Role of cyclins, cyclin dependent kinases (CDKs), growth suppressor genes and cyclin-dependent kinase inhibitors (CKIs) Oncogene 11 1995 211 219
    • (1995) Oncogene , vol.11 , pp. 211-219
    • Grana, X.1    Reddy, E.P.2
  • 47
    • 84874518093 scopus 로고    scopus 로고
    • Frequency and spectrum of BRAF mutations in a retrospective, single-institution study of 1112 cases of melanoma
    • W.O. Greaves, S. Verma, K.P. Patel, M.A. Davies, B.A. Barkoh, and J.M. Galbincea Frequency and spectrum of BRAF mutations in a retrospective, single-institution study of 1112 cases of melanoma J Mol Diagn 15 2013 220 226
    • (2013) J Mol Diagn , vol.15 , pp. 220-226
    • Greaves, W.O.1    Verma, S.2    Patel, K.P.3    Davies, M.A.4    Barkoh, B.A.5    Galbincea, J.M.6
  • 48
    • 33645510413 scopus 로고    scopus 로고
    • Spontaneous and UV radiation-induced multiple metastatic melanomas in Cdk4R24C/R24C/TPras mice
    • E. Hacker, H.K. Muller, N. Irwin, B. Gabrielli, D. Lincoln, and S. Pavey Spontaneous and UV radiation-induced multiple metastatic melanomas in Cdk4R24C/R24C/TPras mice Cancer Res 66 2006 2946 2952
    • (2006) Cancer Res , vol.66 , pp. 2946-2952
    • Hacker, E.1    Muller, H.K.2    Irwin, N.3    Gabrielli, B.4    Lincoln, D.5    Pavey, S.6
  • 49
    • 0034614637 scopus 로고    scopus 로고
    • The hallmarks of cancer
    • D. Hanahan, and R.A. Weinberg The hallmarks of cancer Cell 100 2000 57 70
    • (2000) Cell , vol.100 , pp. 57-70
    • Hanahan, D.1    Weinberg, R.A.2
  • 50
  • 51
    • 84864285704 scopus 로고    scopus 로고
    • Dabrafenib in BRAF-mutated metastatic melanoma: A multicentre, open-label, phase 3 randomised controlled trial
    • A. Hauschild, J.J. Grob, L.V. Demidov, T. Jouary, R. Gutzmer, and M. Millward Dabrafenib in BRAF-mutated metastatic melanoma: A multicentre, open-label, phase 3 randomised controlled trial Lancet 380 2012 358 365
    • (2012) Lancet , vol.380 , pp. 358-365
    • Hauschild, A.1    Grob, J.J.2    Demidov, L.V.3    Jouary, T.4    Gutzmer, R.5    Millward, M.6
  • 52
    • 0038795172 scopus 로고    scopus 로고
    • Genetics of melanoma predisposition
    • N.K. Hayward Genetics of melanoma predisposition Oncogene 22 2003 3053 3062
    • (2003) Oncogene , vol.22 , pp. 3053-3062
    • Hayward, N.K.1
  • 53
    • 74849109743 scopus 로고    scopus 로고
    • Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF
    • S.J. Heidorn, C. Milagre, S. Whittaker, A. Nourry, I. Niculescu-Duvas, and N. Dhomen Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF Cell 140 2010 209 221
    • (2010) Cell , vol.140 , pp. 209-221
    • Heidorn, S.J.1    Milagre, C.2    Whittaker, S.3    Nourry, A.4    Niculescu-Duvas, I.5    Dhomen, N.6
  • 56
    • 84877825519 scopus 로고    scopus 로고
    • RAF inhibitors activate the MAPK pathway by relieving inhibitory autophosphorylation
    • M. Holderfield, H. Merritt, J. Chan, M. Wallroth, L. Tandeske, and H. Zhai RAF inhibitors activate the MAPK pathway by relieving inhibitory autophosphorylation Cancer Cell 23 2013 594 602
    • (2013) Cancer Cell , vol.23 , pp. 594-602
    • Holderfield, M.1    Merritt, H.2    Chan, J.3    Wallroth, M.4    Tandeske, L.5    Zhai, H.6
  • 57
    • 84890621086 scopus 로고    scopus 로고
    • BRAF fusions define a distinct molecular subset of melanomas with potential sensitivity to MEK inhibition
    • K.E. Hutchinson, D. Lipson, P.J. Stephens, G. Otto, B.D. Lehmann, and P.L. Lyle BRAF fusions define a distinct molecular subset of melanomas with potential sensitivity to MEK inhibition Clin Cancer Res 19 2013 6696 6702
    • (2013) Clin Cancer Res , vol.19 , pp. 6696-6702
    • Hutchinson, K.E.1    Lipson, D.2    Stephens, P.J.3    Otto, G.4    Lehmann, B.D.5    Lyle, P.L.6
  • 58
    • 10744232660 scopus 로고    scopus 로고
    • Functional analysis of mutations within the kinase activation segment of B-Raf in human colorectal tumors
    • T. Ikenoue, Y. Hikiba, F. Kanai, Y. Tanaka, J. Imamura, and T. Imamura Functional analysis of mutations within the kinase activation segment of B-Raf in human colorectal tumors Cancer Res 63 2003 8132 8137
    • (2003) Cancer Res , vol.63 , pp. 8132-8137
    • Ikenoue, T.1    Hikiba, Y.2    Kanai, F.3    Tanaka, Y.4    Imamura, J.5    Imamura, T.6
  • 59
    • 84866410479 scopus 로고    scopus 로고
    • Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing
    • M. Imielinski, A.H. Berger, P.S. Hammerman, B. Hernandez, T.J. Pugh, and E. Hodis Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing Cell 150 2012 1107 1120
    • (2012) Cell , vol.150 , pp. 1107-1120
    • Imielinski, M.1    Berger, A.H.2    Hammerman, P.S.3    Hernandez, B.4    Pugh, T.J.5    Hodis, E.6
  • 61
    • 0035150990 scopus 로고    scopus 로고
    • Growth-factor-dependent mitogenesis requires two distinct phases of signalling
    • S.M. Jones, and A. Kazlauskas Growth-factor-dependent mitogenesis requires two distinct phases of signalling Nat Cell Biol 3 2001 165 172
    • (2001) Nat Cell Biol , vol.3 , pp. 165-172
    • Jones, S.M.1    Kazlauskas, A.2
  • 62
    • 55349107544 scopus 로고    scopus 로고
    • Tandem duplication producing a novel oncogenic BRAF fusion gene defines the majority of pilocytic astrocytomas
    • D.T. Jones, S. Kocialkowski, L. Liu, D.M. Pearson, L.M. Backlund, and K. Ichimura Tandem duplication producing a novel oncogenic BRAF fusion gene defines the majority of pilocytic astrocytomas Cancer Res 68 2008 8673 8677
    • (2008) Cancer Res , vol.68 , pp. 8673-8677
    • Jones, D.T.1    Kocialkowski, S.2    Liu, L.3    Pearson, D.M.4    Backlund, L.M.5    Ichimura, K.6
  • 63
    • 77957089182 scopus 로고    scopus 로고
    • The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner
    • E.W. Joseph, C.A. Pratilas, P.I. Poulikakos, M. Tadi, W. Wang, and B.S. Taylor The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner Proc Natl Acad Sci U S A 107 2010 14903 14908
    • (2010) Proc Natl Acad Sci U S A , vol.107 , pp. 14903-14908
    • Joseph, E.W.1    Pratilas, C.A.2    Poulikakos, P.I.3    Tadi, M.4    Wang, W.5    Taylor, B.S.6
  • 64
    • 0037418002 scopus 로고    scopus 로고
    • Components of the Rb pathway are critical targets of UV mutagenesis in a murine melanoma model
    • K. Kannan, N.E. Sharpless, J. Xu, R.C. O'Hagan, M. Bosenberg, and L. Chin Components of the Rb pathway are critical targets of UV mutagenesis in a murine melanoma model Proc Natl Acad Sci U S A 100 2003 1221 1225
    • (2003) Proc Natl Acad Sci U S A , vol.100 , pp. 1221-1225
    • Kannan, K.1    Sharpless, N.E.2    Xu, J.3    O'Hagan, R.C.4    Bosenberg, M.5    Chin, L.6
  • 65
    • 9244251125 scopus 로고    scopus 로고
    • Cell-cycle checkpoints and cancer
    • M.B. Kastan, and J. Bartek Cell-cycle checkpoints and cancer Nature 432 2004 316 323
    • (2004) Nature , vol.432 , pp. 316-323
    • Kastan, M.B.1    Bartek, J.2
  • 66
    • 84874777853 scopus 로고    scopus 로고
    • Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor
    • K.B. Kim, R. Kefford, A.C. Pavlick, J.R. Infante, A. Ribas, and J.A. Sosman Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor J Clin Oncol 31 2013 482 489
    • (2013) J Clin Oncol , vol.31 , pp. 482-489
    • Kim, K.B.1    Kefford, R.2    Pavlick, A.C.3    Infante, J.R.4    Ribas, A.5    Sosman, J.A.6
  • 67
    • 84877853153 scopus 로고    scopus 로고
    • Clinical implication of the BRAFV600E mutation in papillary thyroid carcinoma
    • Y.S. Kim, J.S. Kim, J.S. Bae, and W.C. Park Clinical implication of the BRAFV600E mutation in papillary thyroid carcinoma World J Surg Oncol 11 2013 99
    • (2013) World J Surg Oncol , vol.11 , pp. 99
    • Kim, Y.S.1    Kim, J.S.2    Bae, J.S.3    Park, W.C.4
  • 68
    • 59349108429 scopus 로고    scopus 로고
    • Transcriptional regulation of the cyclin D1 gene at a glance
    • E.A. Klein, and R.K. Assoian Transcriptional regulation of the cyclin D1 gene at a glance J Cell Sci 121 2008 3853 3857
    • (2008) J Cell Sci , vol.121 , pp. 3853-3857
    • Klein, E.A.1    Assoian, R.K.2
  • 69
    • 50149084928 scopus 로고    scopus 로고
    • Tailoring to RB: Tumour suppressor status and therapeutic response
    • E.S. Knudsen, and K.E. Knudsen Tailoring to RB: Tumour suppressor status and therapeutic response Nat Rev Cancer 8 2008 714 724
    • (2008) Nat Rev Cancer , vol.8 , pp. 714-724
    • Knudsen, E.S.1    Knudsen, K.E.2
  • 70
    • 79952710710 scopus 로고    scopus 로고
    • Expression of p16 and retinoblastoma determines response to CDK4/6 inhibition in ovarian cancer
    • G.E. Konecny, B. Winterhoff, T. Kolarova, J. Qi, K. Manivong, and J. Dering Expression of p16 and retinoblastoma determines response to CDK4/6 inhibition in ovarian cancer Clin Cancer Res 17 2011 1591 1602
    • (2011) Clin Cancer Res , vol.17 , pp. 1591-1602
    • Konecny, G.E.1    Winterhoff, B.2    Kolarova, T.3    Qi, J.4    Manivong, K.5    Dering, J.6
  • 71
    • 84870289371 scopus 로고    scopus 로고
    • Oncogenic NRAS signaling differentially regulates survival and proliferation in melanoma
    • L.N. Kwong, J.C. Costello, H. Liu, S. Jiang, T.L. Helms, and A.E. Langsdorf Oncogenic NRAS signaling differentially regulates survival and proliferation in melanoma Nat Med 18 2012 1503 1510
    • (2012) Nat Med , vol.18 , pp. 1503-1510
    • Kwong, L.N.1    Costello, J.C.2    Liu, H.3    Jiang, S.4    Helms, T.L.5    Langsdorf, A.E.6
  • 72
    • 67650073265 scopus 로고    scopus 로고
    • Cell cycle kinases as therapeutic targets for cancer
    • S. Lapenna, and A. Giordano Cell cycle kinases as therapeutic targets for cancer Nat Rev Drug Discov 8 2009 547 566
    • (2009) Nat Rev Drug Discov , vol.8 , pp. 547-566
    • Lapenna, S.1    Giordano, A.2
  • 73
    • 84862697903 scopus 로고    scopus 로고
    • A novel SND1-BRAF fusion confers resistance to c-Met inhibitor PF-04217903 in GTL16 cells through [corrected] MAPK activation
    • N.V. Lee, M.E. Lira, A. Pavlicek, J. Ye, D. Buckman, and S. Bagrodia A novel SND1-BRAF fusion confers resistance to c-Met inhibitor PF-04217903 in GTL16 cells through [corrected] MAPK activation PLoS One 7 2012 e39653
    • (2012) PLoS One , vol.7 , pp. e39653
    • Lee, N.V.1    Lira, M.E.2    Pavlicek, A.3    Ye, J.4    Buckman, D.5    Bagrodia, S.6
  • 74
    • 84861210266 scopus 로고    scopus 로고
    • Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma
    • J.P. Leonard, A.S. LaCasce, M.R. Smith, A. Noy, L.R. Chirieac, and S.J. Rodig Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma Blood 119 2012 4597 4607
    • (2012) Blood , vol.119 , pp. 4597-4607
    • Leonard, J.P.1    Lacasce, A.S.2    Smith, M.R.3    Noy, A.4    Chirieac, L.R.5    Rodig, S.J.6
  • 75
    • 84887478023 scopus 로고    scopus 로고
    • Tumor adaptation and resistance to RAF inhibitors
    • P. Lito, N. Rosen, and D.B. Solit Tumor adaptation and resistance to RAF inhibitors Nat Med 19 2013 1401 1409
    • (2013) Nat Med , vol.19 , pp. 1401-1409
    • Lito, P.1    Rosen, N.2    Solit, D.B.3
  • 76
    • 84868120907 scopus 로고    scopus 로고
    • Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): A multicentre, open-label, phase 2 trial
    • G.V. Long, U. Trefzer, M.A. Davies, R.F. Kefford, P.A. Ascierto, and P.B. Chapman Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): A multicentre, open-label, phase 2 trial Lancet Oncol 13 2012 1087 1095
    • (2012) Lancet Oncol , vol.13 , pp. 1087-1095
    • Long, G.V.1    Trefzer, U.2    Davies, M.A.3    Kefford, R.F.4    Ascierto, P.A.5    Chapman, P.B.6
  • 77
    • 77954152739 scopus 로고    scopus 로고
    • Ubiquitylation and proteasomal degradation of the p21(Cip1), p27(Kip1) and p57(Kip2) CDK inhibitors
    • Z. Lu, and T. Hunter Ubiquitylation and proteasomal degradation of the p21(Cip1), p27(Kip1) and p57(Kip2) CDK inhibitors Cell Cycle 9 2010 2342 2352
    • (2010) Cell Cycle , vol.9 , pp. 2342-2352
    • Lu, Z.1    Hunter, T.2
  • 78
    • 0035754080 scopus 로고    scopus 로고
    • To cycle or not to cycle: A critical decision in cancer
    • M. Malumbres, and M. Barbacid To cycle or not to cycle: A critical decision in cancer Nat Rev Cancer 1 2001 222 231
    • (2001) Nat Rev Cancer , vol.1 , pp. 222-231
    • Malumbres, M.1    Barbacid, M.2
  • 79
    • 60749109846 scopus 로고    scopus 로고
    • Cell cycle, CDKs and cancer: A changing paradigm
    • M. Malumbres, and M. Barbacid Cell cycle, CDKs and cancer: A changing paradigm Nat Rev Cancer 9 2009 153 166
    • (2009) Nat Rev Cancer , vol.9 , pp. 153-166
    • Malumbres, M.1    Barbacid, M.2
  • 80
    • 4444247138 scopus 로고    scopus 로고
    • Mammalian cells cycle without the D-type cyclin-dependent kinases Cdk4 and Cdk6
    • M. Malumbres, R. Sotillo, D. Santamaria, J. Galan, A. Cerezo, and S. Ortega Mammalian cells cycle without the D-type cyclin-dependent kinases Cdk4 and Cdk6 Cell 118 2004 493 504
    • (2004) Cell , vol.118 , pp. 493-504
    • Malumbres, M.1    Sotillo, R.2    Santamaria, D.3    Galan, J.4    Cerezo, A.5    Ortega, S.6
  • 81
    • 84857654700 scopus 로고    scopus 로고
    • RB: Mitotic implications of a tumour suppressor
    • A.L. Manning, and N.J. Dyson RB: Mitotic implications of a tumour suppressor Nat Rev Cancer 12 2012 220 226
    • (2012) Nat Rev Cancer , vol.12 , pp. 220-226
    • Manning, A.L.1    Dyson, N.J.2
  • 82
    • 84873360893 scopus 로고    scopus 로고
    • Resistance to BRAF inhibition in BRAF-mutant colon cancer can be overcome with PI3K inhibition or demethylating agents
    • M. Mao, F. Tian, J.M. Mariadason, C.C. Tsao, R. Lemos Jr., and F. Dayyani Resistance to BRAF inhibition in BRAF-mutant colon cancer can be overcome with PI3K inhibition or demethylating agents Clin Cancer Res 19 2013 657 667
    • (2013) Clin Cancer Res , vol.19 , pp. 657-667
    • Mao, M.1    Tian, F.2    Mariadason, J.M.3    Tsao, C.C.4    Lemos, Jr.R.5    Dayyani, F.6
  • 83
    • 9244239811 scopus 로고    scopus 로고
    • G1 cell-cycle control and cancer
    • J. Massague G1 cell-cycle control and cancer Nature 432 2004 298 306
    • (2004) Nature , vol.432 , pp. 298-306
    • Massague, J.1
  • 86
    • 49649118852 scopus 로고    scopus 로고
    • Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma
    • C. Montagut, S.V. Sharma, T. Shioda, U. McDermott, M. Ulman, and L.E. Ulkus Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma Cancer Res 68 2008 4853 4861
    • (2008) Cancer Res , vol.68 , pp. 4853-4861
    • Montagut, C.1    Sharma, S.V.2    Shioda, T.3    McDermott, U.4    Ulman, M.5    Ulkus, L.E.6
  • 87
    • 84877631604 scopus 로고    scopus 로고
    • Relief of feedback inhibition of HER3 transcription by RAF and MEK inhibitors attenuates their antitumor effects in BRAF-mutant thyroid carcinomas
    • C. Montero-Conde, S. Ruiz-Llorente, J.M. Dominguez, J.A. Knauf, A. Viale, and E.J. Sherman Relief of feedback inhibition of HER3 transcription by RAF and MEK inhibitors attenuates their antitumor effects in BRAF-mutant thyroid carcinomas Cancer Discov 3 2013 520 533
    • (2013) Cancer Discov , vol.3 , pp. 520-533
    • Montero-Conde, C.1    Ruiz-Llorente, S.2    Dominguez, J.M.3    Knauf, J.A.4    Viale, A.5    Sherman, E.J.6
  • 88
    • 84908219463 scopus 로고    scopus 로고
    • Progression-Free Survival Remains Poor over Sequential Lines of Systemic Therapy in Patients with BRAF-Mutated Colorectal Cancer
    • V. Morris, M.J. Overman, Z.Q. Jiang, C. Garrett, S. Agarwal, and C. Eng Progression-Free Survival Remains Poor Over Sequential Lines of Systemic Therapy in Patients With BRAF-Mutated Colorectal Cancer Clin Colorectal Cancer 13 2014 164 171
    • (2014) Clin Colorectal Cancer , vol.13 , pp. 164-171
    • Morris, V.1    Overman, M.J.2    Jiang, Z.Q.3    Garrett, C.4    Agarwal, S.5    Eng, C.6
  • 90
    • 33646345376 scopus 로고    scopus 로고
    • Ubiquitin ligases: Cell-cycle control and cancer
    • K.I. Nakayama, and K. Nakayama Ubiquitin ligases: Cell-cycle control and cancer Nat Rev Cancer 6 2006 369 381
    • (2006) Nat Rev Cancer , vol.6 , pp. 369-381
    • Nakayama, K.I.1    Nakayama, K.2
  • 91
    • 84883482902 scopus 로고    scopus 로고
    • Tumor genetic analyses of patients with metastatic melanoma treated with the BRAF inhibitor dabrafenib (GSK2118436)
    • K.L. Nathanson, A.M. Martin, B. Wubbenhorst, J. Greshock, R. Letrero, and K. D'Andrea Tumor genetic analyses of patients with metastatic melanoma treated with the BRAF inhibitor dabrafenib (GSK2118436) Clin Cancer Res 19 2013 4868 4878
    • (2013) Clin Cancer Res , vol.19 , pp. 4868-4878
    • Nathanson, K.L.1    Martin, A.M.2    Wubbenhorst, B.3    Greshock, J.4    Letrero, R.5    D'Andrea, K.6
  • 92
    • 78650303507 scopus 로고    scopus 로고
    • Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation
    • R. Nazarian, H. Shi, Q. Wang, X. Kong, R.C. Koya, and H. Lee Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation Nature 468 2010 973 977
    • (2010) Nature , vol.468 , pp. 973-977
    • Nazarian, R.1    Shi, H.2    Wang, Q.3    Kong, X.4    Koya, R.C.5    Lee, H.6
  • 94
    • 79953325104 scopus 로고    scopus 로고
    • PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression
    • K.H. Paraiso, Y. Xiang, V.W. Rebecca, E.V. Abel, Y.A. Chen, and A.C. Munko PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression Cancer Res 71 2011 2750 2760
    • (2011) Cancer Res , vol.71 , pp. 2750-2760
    • Paraiso, K.H.1    Xiang, Y.2    Rebecca, V.W.3    Abel, E.V.4    Chen, Y.A.5    Munko, A.C.6
  • 96
    • 83455254767 scopus 로고    scopus 로고
    • RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)
    • P.I. Poulikakos, Y. Persaud, M. Janakiraman, X. Kong, C. Ng, and G. Moriceau RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E) Nature 480 2011 387 390
    • (2011) Nature , vol.480 , pp. 387-390
    • Poulikakos, P.I.1    Persaud, Y.2    Janakiraman, M.3    Kong, X.4    Ng, C.5    Moriceau, G.6
  • 97
    • 78651418282 scopus 로고    scopus 로고
    • Mutant BRAF melanomas-dependence and resistance
    • P.I. Poulikakos, and N. Rosen Mutant BRAF melanomas-dependence and resistance Cancer Cell 19 2011 11 15
    • (2011) Cancer Cell , vol.19 , pp. 11-15
    • Poulikakos, P.I.1    Rosen, N.2
  • 98
    • 77949732073 scopus 로고    scopus 로고
    • RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF
    • P.I. Poulikakos, C. Zhang, G. Bollag, K.M. Shokat, and N. Rosen RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF Nature 464 2010 427 430
    • (2010) Nature , vol.464 , pp. 427-430
    • Poulikakos, P.I.1    Zhang, C.2    Bollag, G.3    Shokat, K.M.4    Rosen, N.5
  • 99
    • 84863230465 scopus 로고    scopus 로고
    • Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR
    • A. Prahallad, C. Sun, S. Huang, F. Di Nicolantonio, R. Salazar, and D. Zecchin Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR Nature 483 2012 100 103
    • (2012) Nature , vol.483 , pp. 100-103
    • Prahallad, A.1    Sun, C.2    Huang, S.3    Di Nicolantonio, F.4    Salazar, R.5    Zecchin, D.6
  • 100
    • 77954279920 scopus 로고    scopus 로고
    • A synthetic lethal interaction between K-Ras oncogenes and Cdk4 unveils a therapeutic strategy for non-small cell lung carcinoma
    • M. Puyol, A. Martin, P. Dubus, F. Mulero, P. Pizcueta, and G. Khan A synthetic lethal interaction between K-Ras oncogenes and Cdk4 unveils a therapeutic strategy for non-small cell lung carcinoma Cancer Cell 18 2010 63 73
    • (2010) Cancer Cell , vol.18 , pp. 63-73
    • Puyol, M.1    Martin, A.2    Dubus, P.3    Mulero, F.4    Pizcueta, P.5    Khan, G.6
  • 104
    • 79958149971 scopus 로고    scopus 로고
    • Phase i study of PD 0332991, a cyclin-dependent kinase inhibitor, administered in 3-week cycles (Schedule 2/1)
    • G.K. Schwartz, P.M. LoRusso, M.A. Dickson, S.S. Randolph, M.N. Shaik, and K.D. Wilner Phase I study of PD 0332991, a cyclin-dependent kinase inhibitor, administered in 3-week cycles (Schedule 2/1) Br J Cancer 104 2011 1862 1868
    • (2011) Br J Cancer , vol.104 , pp. 1862-1868
    • Schwartz, G.K.1    Lorusso, P.M.2    Dickson, M.A.3    Randolph, S.S.4    Shaik, M.N.5    Wilner, K.D.6
  • 105
    • 33745018419 scopus 로고    scopus 로고
    • Mutually exclusive NRASQ61R and BRAFV600E mutations at the single-cell level in the same human melanoma
    • M. Sensi, G. Nicolini, C. Petti, I. Bersani, F. Lozupone, and A. Molla Mutually exclusive NRASQ61R and BRAFV600E mutations at the single-cell level in the same human melanoma Oncogene 25 2006 3357 3364
    • (2006) Oncogene , vol.25 , pp. 3357-3364
    • Sensi, M.1    Nicolini, G.2    Petti, C.3    Bersani, I.4    Lozupone, F.5    Molla, A.6
  • 108
    • 84925624987 scopus 로고    scopus 로고
    • Genomic alterations of the CDK4-pathway in melanoma and evaluation of the CDK4 Inhibitor PD-0332991
    • K.E. Sheppard, A. Foo, R. Young, K. Waldeck, R. Pearson, and G. McArthur Genomic alterations of the CDK4-pathway in melanoma and evaluation of the CDK4 Inhibitor PD-0332991 Cancer Res 73 2013
    • (2013) Cancer Res , vol.73
    • Sheppard, K.E.1    Foo, A.2    Young, R.3    Waldeck, K.4    Pearson, R.5    McArthur, G.6
  • 109
    • 0029330474 scopus 로고
    • Mammalian G1 cyclins and cell cycle progression
    • C.J. Sherr Mammalian G1 cyclins and cell cycle progression Proc Assoc Am Physicians 107 1995 181 186
    • (1995) Proc Assoc Am Physicians , vol.107 , pp. 181-186
    • Sherr, C.J.1
  • 110
    • 8644219655 scopus 로고    scopus 로고
    • Living with or without cyclins and cyclin-dependent kinases
    • C.J. Sherr, and J.M. Roberts Living with or without cyclins and cyclin-dependent kinases Genes Dev 18 2004 2699 2711
    • (2004) Genes Dev , vol.18 , pp. 2699-2711
    • Sherr, C.J.1    Roberts, J.M.2
  • 111
    • 84891898344 scopus 로고    scopus 로고
    • Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy
    • H. Shi, W. Hugo, X. Kong, A. Hong, R.C. Koya, and G. Moriceau Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy Cancer Discov 4 2014 80 93
    • (2014) Cancer Discov , vol.4 , pp. 80-93
    • Shi, H.1    Hugo, W.2    Kong, X.3    Hong, A.4    Koya, R.C.5    Moriceau, G.6
  • 112
    • 84859183431 scopus 로고    scopus 로고
    • Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance
    • H. Shi, G. Moriceau, X. Kong, M.K. Lee, H. Lee, and R.C. Koya Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance Nat Commun 3 2012 724
    • (2012) Nat Commun , vol.3 , pp. 724
    • Shi, H.1    Moriceau, G.2    Kong, X.3    Lee, M.K.4    Lee, H.5    Koya, R.C.6
  • 113
    • 33745075558 scopus 로고    scopus 로고
    • Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases
    • K.S. Smalley, N.K. Haass, P.A. Brafford, M. Lioni, K.T. Flaherty, and M. Herlyn Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases Mol Cancer Ther 5 2006 1136 1144
    • (2006) Mol Cancer Ther , vol.5 , pp. 1136-1144
    • Smalley, K.S.1    Haass, N.K.2    Brafford, P.A.3    Lioni, M.4    Flaherty, K.T.5    Herlyn, M.6
  • 114
    • 54049158957 scopus 로고    scopus 로고
    • Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E-mutated melanomas
    • K.S. Smalley, M. Lioni, M. Dalla Palma, M. Xiao, B. Desai, and S. Egyhazi Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E-mutated melanomas Mol Cancer Ther 7 2008 2876 2883
    • (2008) Mol Cancer Ther , vol.7 , pp. 2876-2883
    • Smalley, K.S.1    Lioni, M.2    Dalla Palma, M.3    Xiao, M.4    Desai, B.5    Egyhazi, S.6
  • 115
    • 84912110744 scopus 로고    scopus 로고
    • A phase 1b/2 study of LEE011 in combination with binimetinib (MEK162) in patients with NRAS-mutant melanoma: Early encouraging clinical activity
    • J.A. Sosman, M. Kittaneh, M.P.J.K. Lolkema, M.A. Postow, G. Schwartz, and C. Franklin A phase 1b/2 study of LEE011 in combination with binimetinib (MEK162) in patients with NRAS-mutant melanoma: Early encouraging clinical activity ASCO Meeting Abstracts 32 2014 9009
    • (2014) ASCO Meeting Abstracts , vol.32 , pp. 9009
    • Sosman, J.A.1    Kittaneh, M.2    Lolkema, M.P.J.K.3    Postow, M.A.4    Schwartz, G.5    Franklin, C.6
  • 117
    • 84864285794 scopus 로고    scopus 로고
    • Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion
    • R. Straussman, T. Morikawa, K. Shee, M. Barzily-Rokni, Z.R. Qian, and J. Du Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion Nature 487 2012 500 504
    • (2012) Nature , vol.487 , pp. 500-504
    • Straussman, R.1    Morikawa, T.2    Shee, K.3    Barzily-Rokni, M.4    Qian, Z.R.5    Du, J.6
  • 118
    • 84863115580 scopus 로고    scopus 로고
    • Resistance to Selective BRAF Inhibition Can Be Mediated by Modest Upstream Pathway Activation
    • F. Su, W.D. Bradley, Q. Wang, H. Yang, L. Xu, and B. Higgins Resistance to Selective BRAF Inhibition Can Be Mediated by Modest Upstream Pathway Activation Cancer Res 72 2012 969 978
    • (2012) Cancer Res , vol.72 , pp. 969-978
    • Su, F.1    Bradley, W.D.2    Wang, Q.3    Yang, H.4    Xu, L.5    Higgins, B.6
  • 119
    • 84875675990 scopus 로고    scopus 로고
    • Constant activation of the RAF-MEK-ERK pathway as a diagnostic and therapeutic target in hairy cell leukemia
    • E. Tiacci, G. Schiavoni, M.P. Martelli, E. Boveri, R. Pacini, and A. Tabarrini Constant activation of the RAF-MEK-ERK pathway as a diagnostic and therapeutic target in hairy cell leukemia Haematologica 98 2013 635 639
    • (2013) Haematologica , vol.98 , pp. 635-639
    • Tiacci, E.1    Schiavoni, G.2    Martelli, M.P.3    Boveri, E.4    Pacini, R.5    Tabarrini, A.6
  • 120
  • 122
    • 78650008177 scopus 로고    scopus 로고
    • Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K
    • J. Villanueva, A. Vultur, J.T. Lee, R. Somasundaram, M. Fukunaga-Kalabis, and A.K. Cipolla Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K Cancer Cell 18 2010 683 695
    • (2010) Cancer Cell , vol.18 , pp. 683-695
    • Villanueva, J.1    Vultur, A.2    Lee, J.T.3    Somasundaram, R.4    Fukunaga-Kalabis, M.5    Cipolla, A.K.6
  • 123
    • 80051625929 scopus 로고    scopus 로고
    • Dissecting Therapeutic Resistance to RAF Inhibition in Melanoma by Tumor Genomic Profiling
    • N. Wagle, C. Emery, M.F. Berger, M.J. Davis, A. Sawyer, and P. Pochanard Dissecting Therapeutic Resistance to RAF Inhibition in Melanoma by Tumor Genomic Profiling J Clin Oncol 29 2011 3085 3096
    • (2011) J Clin Oncol , vol.29 , pp. 3085-3096
    • Wagle, N.1    Emery, C.2    Berger, M.F.3    Davis, M.J.4    Sawyer, A.5    Pochanard, P.6
  • 124
    • 0031980540 scopus 로고    scopus 로고
    • Virtually 100% of melanoma cell lines harbor alterations at the DNA level within CDKN2A, CDKN2B, or one of their downstream targets
    • G.J. Walker, J.F. Flores, J.M. Glendening, A.H. Lin, I.D. Markl, and J.W. Fountain Virtually 100% of melanoma cell lines harbor alterations at the DNA level within CDKN2A, CDKN2B, or one of their downstream targets Genes Chromosomes Cancer 22 1998 157 163
    • (1998) Genes Chromosomes Cancer , vol.22 , pp. 157-163
    • Walker, G.J.1    Flores, J.F.2    Glendening, J.M.3    Lin, A.H.4    Markl, I.D.5    Fountain, J.W.6
  • 125
    • 12144289677 scopus 로고    scopus 로고
    • Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF
    • P.T. Wan, M.J. Garnett, S.M. Roe, S. Lee, D. Niculescu-Duvaz, and V.M. Good Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF Cell 116 2004 855 867
    • (2004) Cell , vol.116 , pp. 855-867
    • Wan, P.T.1    Garnett, M.J.2    Roe, S.M.3    Lee, S.4    Niculescu-Duvaz, D.5    Good, V.M.6
  • 126
    • 34548838818 scopus 로고    scopus 로고
    • Pharmacologic inhibition of CDK4/6: Mechanistic evidence for selective activity or acquired resistance in acute myeloid leukemia
    • L. Wang, J. Wang, B.W. Blaser, A.M. Duchemin, D.F. Kusewitt, and T. Liu Pharmacologic inhibition of CDK4/6: Mechanistic evidence for selective activity or acquired resistance in acute myeloid leukemia Blood 110 2007 2075 2082
    • (2007) Blood , vol.110 , pp. 2075-2082
    • Wang, L.1    Wang, J.2    Blaser, B.W.3    Duchemin, A.M.4    Kusewitt, D.F.5    Liu, T.6
  • 131
    • 4944249117 scopus 로고    scopus 로고
    • BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis
    • S.M. Wilhelm, C. Carter, L. Tang, D. Wilkie, A. McNabola, and H. Rong BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis Cancer Res 64 2004 7099 7109
    • (2004) Cancer Res , vol.64 , pp. 7099-7109
    • Wilhelm, S.M.1    Carter, C.2    Tang, L.3    Wilkie, D.4    McNabola, A.5    Rong, H.6
  • 132
    • 84871390702 scopus 로고    scopus 로고
    • Intratumoral molecular heterogeneity in a BRAF-mutant, BRAF inhibitor-resistant melanoma: A case illustrating the challenges for personalized medicine
    • J.S. Wilmott, V. Tembe, J.R. Howle, R. Sharma, J.F. Thompson, and H. Rizos Intratumoral molecular heterogeneity in a BRAF-mutant, BRAF inhibitor-resistant melanoma: A case illustrating the challenges for personalized medicine Mol Cancer Ther 11 2012 2704 2708
    • (2012) Mol Cancer Ther , vol.11 , pp. 2704-2708
    • Wilmott, J.S.1    Tembe, V.2    Howle, J.R.3    Sharma, R.4    Thompson, J.F.5    Rizos, H.6
  • 133
    • 84864286442 scopus 로고    scopus 로고
    • Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors
    • T.R. Wilson, J. Fridlyand, Y. Yan, E. Penuel, L. Burton, and E. Chan Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors Nature 487 2012 505 509
    • (2012) Nature , vol.487 , pp. 505-509
    • Wilson, T.R.1    Fridlyand, J.2    Yan, Y.3    Penuel, E.4    Burton, L.5    Chan, E.6
  • 134
    • 84856217925 scopus 로고    scopus 로고
    • Concurrent loss of the PTEN and RB1 tumor suppressors attenuates RAF dependence in melanomas harboring (V600E)BRAF
    • F. Xing, Y. Persaud, C.A. Pratilas, B.S. Taylor, M. Janakiraman, and Q.B. She Concurrent loss of the PTEN and RB1 tumor suppressors attenuates RAF dependence in melanomas harboring (V600E)BRAF Oncogene 31 2012 446 457
    • (2012) Oncogene , vol.31 , pp. 446-457
    • Xing, F.1    Persaud, Y.2    Pratilas, C.A.3    Taylor, B.S.4    Janakiraman, M.5    She, Q.B.6
  • 135
    • 84925604287 scopus 로고    scopus 로고
    • The CDK4/6 Inhibitor LY2835219 Overcomes Vemurafenib Resistance Resulting from MAPK Reactivation and Cyclin D1 Upregulation
    • V. Yadav, T.F. Burke, L. Huber, R.D. Van Horn, Y. Zhang, and S.G. Buchanan The CDK4/6 Inhibitor LY2835219 Overcomes Vemurafenib Resistance Resulting from MAPK Reactivation and Cyclin D1 Upregulation Mol Cancer Ther 13 2014 2253 2263
    • (2014) Mol Cancer Ther , vol.13 , pp. 2253-2263
    • Yadav, V.1    Burke, T.F.2    Huber, L.3    Van Horn, R.D.4    Zhang, Y.5    Buchanan, S.G.6
  • 136
    • 84864994126 scopus 로고    scopus 로고
    • Reactivation of mitogen-activated protein kinase (MAPK) pathway by FGF receptor 3 (FGFR3)/Ras mediates resistance to vemurafenib in human B-RAF V600E mutant melanoma
    • V. Yadav, X. Zhang, J. Liu, S. Estrem, S. Li, and X.Q. Gong Reactivation of mitogen-activated protein kinase (MAPK) pathway by FGF receptor 3 (FGFR3)/Ras mediates resistance to vemurafenib in human B-RAF V600E mutant melanoma J Biol Chem 287 2012 28087 28098
    • (2012) J Biol Chem , vol.287 , pp. 28087-28098
    • Yadav, V.1    Zhang, X.2    Liu, J.3    Estrem, S.4    Li, S.5    Gong, X.Q.6
  • 137
    • 84855302859 scopus 로고    scopus 로고
    • Intra- and inter-tumor heterogeneity of BRAF(V600E) mutations in primary and metastatic melanoma
    • M. Yancovitz, A. Litterman, J. Yoon, E. Ng, R.L. Shapiro, and R.S. Berman Intra- and inter-tumor heterogeneity of BRAF(V600E) mutations in primary and metastatic melanoma PLoS One 7 2012 e29336
    • (2012) PLoS One , vol.7 , pp. e29336
    • Yancovitz, M.1    Litterman, A.2    Yoon, J.3    Ng, E.4    Shapiro, R.L.5    Berman, R.S.6
  • 138
    • 84863012433 scopus 로고    scopus 로고
    • Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer
    • H. Yang, B. Higgins, K. Kolinsky, K. Packman, W.D. Bradley, and R.J. Lee Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer Cancer Res 72 2012 779 789
    • (2012) Cancer Res , vol.72 , pp. 779-789
    • Yang, H.1    Higgins, B.2    Kolinsky, K.3    Packman, K.4    Bradley, W.D.5    Lee, R.J.6
  • 139
    • 77954376912 scopus 로고    scopus 로고
    • RG7204 (PLX4032), a selective BRAFV600E inhibitor, displays potent antitumor activity in preclinical melanoma models
    • H. Yang, B. Higgins, K. Kolinsky, K. Packman, Z. Go, and R. Iyer RG7204 (PLX4032), a selective BRAFV600E inhibitor, displays potent antitumor activity in preclinical melanoma models Cancer Res 70 2010 5518 5527
    • (2010) Cancer Res , vol.70 , pp. 5518-5527
    • Yang, H.1    Higgins, B.2    Kolinsky, K.3    Packman, K.4    Go, Z.5    Iyer, R.6
  • 140
    • 0037112438 scopus 로고    scopus 로고
    • Similarity of the phenotypic patterns associated with BRAF and KRAS mutations in colorectal neoplasia
    • S.T. Yuen, H. Davies, T.L. Chan, J.W. Ho, G.R. Bignell, and C. Cox Similarity of the phenotypic patterns associated with BRAF and KRAS mutations in colorectal neoplasia Cancer Res 62 2002 6451 6455
    • (2002) Cancer Res , vol.62 , pp. 6451-6455
    • Yuen, S.T.1    Davies, H.2    Chan, T.L.3    Ho, J.W.4    Bignell, G.R.5    Cox, C.6
  • 141
    • 0029664339 scopus 로고    scopus 로고
    • Germline mutations in the p16INK4a binding domain of CDK4 in familial melanoma
    • L. Zuo, J. Weger, Q. Yang, A.M. Goldstein, M.A. Tucker, and G.J. Walker Germline mutations in the p16INK4a binding domain of CDK4 in familial melanoma Nat Genet 12 1996 97 99
    • (1996) Nat Genet , vol.12 , pp. 97-99
    • Zuo, L.1    Weger, J.2    Yang, Q.3    Goldstein, A.M.4    Tucker, M.A.5    Walker, G.J.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.